Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

STA 9090

Known as: Hsp90 Inhibitor STA-9090, STA-9090, STA9090 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BackgroundThis phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations… Expand
  • figure 2
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
10011 Background: Ganetespib, a potent, synthetic small-molecule inhibitor of Hsp90, has shown an improved safety profile… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
7500 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation… Expand
Is this relevant?
2011
2011
Background The novel water soluble compound STA-1474 is metabolized to ganetespib (formerly STA-9090), a potent HSP90 inhibitor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2010
Review
2010
STA-9090 is a second-generation Hsp90 inhibitor in clinical development by Synta Pharmaceuticals for the intravenous treatment of… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Osteosarcoma (OSA), the most common malignant bone tumor in dogs and children, exhibits a similar clinical presentation and… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers. While Kit inhibitors have… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?